A member of the Roche group since 2009, Genentech discovers, develops, manufactures, and commercializes medicines for people with serious or life-threatening diseases. Their approach to the facility, flexibility of the equipment, and ability to implement new technologies rapidly without requiring building modifications, enables Genentech to more easily adapt and accommodate future needs.
Their approach to the facility, flexibility of the equipment, and ability to implement new technologies rapidly without requiring building modifications, enables Genentech to more easily adapt and accommodate future needs.
According to Genentech, “The CSC has been designed to leverage the latest digital technologies along with in-house process improvements that significantly increase production flexibility, efficiency and output while reducing the use of water and energy resources to achieve higher levels of sustainability.”
